Health care resource utilization and costs of patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapies across different settings of care: A real-world data analysis

DLBCL CAR T products were administered predominantly in the inpatient setting. For overall CAR T products for DLBCL and axi-cel, patients receiving CAR T administration in the outpatient setting tended to have lower inpatient service utilizations and lower costs relative to those receiving it in the inpatient setting, suggesting that outpatient CAR T administration may help address capacity constraint and economic burden of CAR T delivery.